Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Venous Leg Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-02

Study Completion Date

2026-03-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective case series evaluating the efficacy and safety of NeoThelium FT Amnion Skin Graft in the Mangement of Venous Leg Ulcers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers

NCT07039396

Diabetic Foot Ulcer

RECRUITING NA

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Chronic Pressure Ulcers

NCT07158658

Pressure Injury

RECRUITING NA

Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers

NCT06930768

Venous Leg Ulcer

NOT_YET_RECRUITING NA

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer

NCT01658618

Venous Leg Ulcer

UNKNOWN

Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds

NCT06918561

Open Wound

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will begin SOC plus NeoThelium FT weekly applications. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

NeoThelium FT in addition to Standard of Care

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NeoThelium FT (HCT/P 361)+ SOC

Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading

Group Type EXPERIMENTAL

NeoThelium FT (HCT/P 361)

Intervention Type OTHER

NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NeoThelium FT (HCT/P 361)

NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or Female, 18 years of age or older
2. Subject has a medical diagnosis of venous leg ulcer or venous insufficiency with a lower extremity wound
3. Subject has an venous leg ulcer without infection or clinically visible exposed bone
4. Index wound is a minimum of 1 cm2 and a maximum of 30 cm2 at first treatment visit
5. Adequate circulation if wound is location on the lower extremity demonstrated by an ABI of \>0.7 and \<1.3, or TBI of \>0.6 within 30 days prior to informed consent OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to the first treatment visit.
6. Venous Leg Ulcer is being treated with compression therapy for 7 days prior to treatment visit 1
7. Index wound is free of necrotic debris prior to NeoThelium FT application
8. Female subjects of childbearing potential having a negative pregnancy test prior to the first treatment visit
9. Wound free of clinical signs/symptoms of infection (no purulent discharge or cellulitis) post-debridement during screening and prior to the first treatment visit.
10. Subject is able and willing to follow the protocol requirements
11. Subject had signed informed consent
12. If 2 or more wounds are present, the wounds must be separated by at least 2 cm

Exclusion Criteria

1. Subject is unable to comply with protocol treatment
2. Presence of infection prior to screening.
3. Multiple VLUs on the same leg with \< 2 cm separation from the target ulcer.
4. Subject has comorbid conditions that may compromise subject safety or wound healing in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders
5. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound.
6. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
7. Known contraindications or hypersensitivity to amniotic membrane products or components of NeoThelium FT.
8. Concurrent participation in alternative clinical trial that involves investigational drug or HCT/P interfering with wound treatment and/or healing.
9. Subject is pregnant or breastfeeding
10. Subject with history of immunosuppressant treatment (systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the ulcer surface for \>2 weeks duration within 30 days prior to the first treatment visit; or anticipated use of the above during the course of the study
11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to enrollment
12. Index ulcer suspicious of neoplasm in the opinion of the principal investigator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No